Navigation Links
NxStage Announces Access to Demographic and Outcomes Information for the Growing U.S. Daily Home Hemodialysis Patient Population
Date:7/23/2008

, Inc., 439 S. Union St., 5th Floor, Lawrence, Massachusetts 01843, Attention: Investor Relations.

NxStage, its directors and the affiliates of its directors may be deemed to be participants in the solicitation of proxies with respect to the private placement. A description of the interests in NxStage of its directors, officers and such affiliates is set forth in NxStage's proxy statement for its 2008 annual meeting of stockholders, filed with the SEC on April 29, 2008, and is included in the definitive proxy statement relating to the private placement and required stockholder approval filed with the SEC on July 8, 2008. These documents are available free of charge as described above.

Investor Relations Contact

Kristen Sheppard

NxStage Medical, Inc.

ir@nxstage.com

978-332-5923

Media Contact

Jane Hauser

Schwartz Communications, Inc.

nxstage@schwartz-pr.com

781-684-0770


'/>"/>
SOURCE NxStage Medical, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. NxStage Medical to Present at the Thomas Weisel Partners Healthcare Conference on September 5, 2007
2. NxStage Medical Provides Update on Medisystems Acquisition
3. NxStage(R) Medical to Report Third Quarter 2007 Financial Results on Friday, November 2nd
4. Arbios Announces SEPET(TM) Manufacturing Agreement With NxStage Medical
5. NxStage Medical to Present at the Piper Jaffray Healthcare Conference on November 27, 2007
6. NxStage Medical Announces Needle Supply Agreement with DaVita
7. NxStage Appoints Tom Shea as Senior Vice President of Manufacturing Operations
8. NxStage Medical to Present at William Blair Growth Stock Conference
9. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
10. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
11. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)...M, Ontario, Nov. 24 Dow ...g the assets of Hyland Seeds, a division of Thomps...Hyland Seeds will further expand Dow AgroSciences,... the introduction of SmartStax(TM) in 2010 a...ology in corn in 2012. The transactional close is ...
(Date:11/24/2009)...YKJAVIK, Iceland, November 24 /PRNewswire-FirstCal...announced the approval of all of its,"first day" m...ct of Delaware,(the "Bankruptcy Court"). deCODE la...r Chapter 11 of the United States Bankruptcy Code ...ssued by the Bankruptcy Court allow the company to...
(Date:11/24/2009)...RNewswire/ -- Blue Marble Energy Corp. announced t...pment Authority (OPDA) were recently awarded $2 mi...italization Board (CERB) in a private/public partn...ochemical biorefinery in Lincoln County, WA. ,...evelopment of our biorefinery and bring over 70 gr...
(Date:11/24/2009)...er 24 Shire plc (LSE: SH...aceutical company, today,announced that it has sub...velaglucerase alfa, the company,s enzyme replaceme...e 1 Gaucher disease. This is the third marketing,a...bmitted, with previous,submissions in the United S...
Breaking Biology Technology:Dow AgroSciences Canada Announces Agreement to Acquire Hyland Seeds 2Dow AgroSciences Canada Announces Agreement to Acquire Hyland Seeds 3deCODE genetics, Inc. Announces Approval of First Day Motions by Bankruptcy Court 2deCODE genetics, Inc. Announces Approval of First Day Motions by Bankruptcy Court 3Blue Marble Energy, OPDA Awarded $2M by WA's Community Economic Revitalization Board 2Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 2Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 3Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 4
...rence Call To Be Held Friday, November 14, 2008 at... Time, HOPKINTON, Mass., Nov. 13 Alseres,Pharma...rational and,financial results for the quarter end...tion for fiscal year 2008., (Logo: http://www.ne...e are encouraged by the progress we have made on o...
...SDA, Md., Nov. 13 Spherix Incorporated,(Nasdaq: ...months ended,September 30, 2008 of $1.7 million ($..., respectively. Research and development and marke...urlose as a treatment for Type,2 diabetes were app...ended,September 30, 2008, compared to approximatel...
...RBOR, Mich., Nov. 13 NanoBio Corporation announce...entations that detail,milestones in its clinical a...is, acne, herpes labialis and genital herpes durin...tists (AAPS) meeting November 16-20,2008 in Atlant...ng the conference:, Tuesday, November 18, 1:00 PM...
Other Biology Technology:Alseres Pharmaceuticals, Inc. Reports Third Quarter 2008 Operational and Financial Results 2Alseres Pharmaceuticals, Inc. Reports Third Quarter 2008 Operational and Financial Results 3Alseres Pharmaceuticals, Inc. Reports Third Quarter 2008 Operational and Financial Results 4Alseres Pharmaceuticals, Inc. Reports Third Quarter 2008 Operational and Financial Results 5Spherix Reports 3rd Quarter Earnings 2NanoBio to Give Four Scientific Presentations at Upcoming National Meeting of Pharmaceutical Scientists 2
(Date:11/24/2009)... NEW YORK (November 24, 2009) -- The Wildlife...rt revealing that the last remaining population of... due to the rising tide of poaching and habitat lo...inform Russian officials of what needs to be done ...ggest cat. , The report was release...
(Date:11/23/2009)...New research presents strong evidence that the "sy...utdoor traffic-related pollution and indoor endoto...or the other exposure alone. , Environmental h...UC) College of Medicine have shown that children e...icles and indoor endotoxin during early life are s...
(Date:11/23/2009)...lif. -- More than 160 participants gathered this w... FUTURES INITIATIVE conference. This year,s topic,... engineers, and medical researchers to explore the...nding the emerging field of synthetic biology. , ... at Princeton University and this year,s conferenc...
Breaking Biology News(10 mins):Report shows dramatic decline in Siberian tigers 2Exposure to both traffic, indoor pollutants puts some kids at higher risk for asthma later 2Synthetic biology offers new opportunities for interdisciplinary collaboration 2Psoriasis Video Contest Launched to Encourage Psoriasis Patients to Connect and Collaborate 54344 1Psoriasis Video Contest Launched to Encourage Psoriasis Patients to Connect and Collaborate 54344 2U S Women Delaying Motherhood Report Shows 54341 1U S Women Delaying Motherhood Report Shows 54341 22009 CMA Medal of Service 54338 12009 CMA Medal of Service 54338 22009 CMA Medal of Service 54338 3
...s a,paradigm in life science and drug development ...p;D companies. In many occasions I,ve,seen very pr...anned,because no money was to be made with it, eve... usual strategy to avoid this fate is to find,a dr... addition to the,"non-profitable" one. PLoS Medeci...
...l application involving the buzzword "nano" - canc... resonance imaging) : ,Accurate staging of cancer...p of patients for both prediction of prognosis and...And an essential part of this work,up is assessing...urrent,methods include surgical removal of nodes f...
...mes a,potential target for a drug seems very promi...reality. Its the case of telomerase inhibitors,to ...rtal" (able to,divide indefinitely) aspect of canc...k their function, preventing them to inhibit compl...roject? Look for something,else? Hell no! Look out...
Other Biology News:Finding Cures For Tropical Diseases: Is Open Source An Answer? 2Imaging Lymph Nodes with Nanoparticles 2GATA: a graphic alignment tool for comparative sequence analysis 2
...via cardiac puncture from 3 to 4 week old rabbits ...uged and frozen at -70C. The complement is thawed,...tored at -70C. DIRECT SALES FROM PEL-FREEZ BIOLOGI..., YOU CAN NOW BUY DIRECTLY FROM THE SOURCE! FORMER...
Dacron mesh button tether single channel infusion of rats, sterile from Instech Solomon
GIBCO Donor Calf Serum from Invitrogen
Genes VI from Promega
Biology Products: